[
{
	"page":"ENAS5281_1.0.0.0",
	"text":"Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth de Vries, Alan Horwich, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2016;27(Suppl 5):V1-27 http://annonc.oxfordjournals.org/content/27/suppl_5/v1.full.pdf+html Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 ESMO Guidelines Committee Ann Oncol 2017; 28(Suppl 4): iv158–61 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv158/18564105/mdx245.pdf Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 ESMO Guidelines Committee Ann Oncol 2017; 28(Suppl 4): iv162–4 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv162/18564107/mdx246.pdf 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S and Panel Members Ann Oncol 2014;25:1475-84 http://annonc.oxfordjournals.org/content/25/8/1475.full.pdf+html 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer Eberhard WEE, De Ruysscher D, Weder W, Le Pechoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S and Panel Members Ann Oncol 2015;26:1573-88 http://annonc.oxfordjournals.org/content/26/8/1573.full.pdf+html 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E and Panel Members Ann Oncol 2014;25:1462-74 http://annonc.oxfordjournals.org/content/25/8/1462.full.pdf+html Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv1–21 https://​academic.oup.com/​annonc/​article-​pdf/​28/​suppl_4/​iv1/​18528229/​mdx222.pdf 2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O’Byrne K, Stahel R, Peters S, Felip E and Panel Members Ann Oncol 2014;25:1681-90 http://annonc.oxfordjournals.org/content/25/9/1681.full.pdf+html Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Früh M, De Ruysscher D, Popat S, Crinò Peters S and Felip E, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi99-105 https://​academic.oup.com/​annonc/​article-pdf/​24/​suppl_6/​vi99/​160407/​mdt178.pdf Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Baas P, Fennell D, Kerr K, Van Schil PE, Haas RL and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(suppl 5):v31-9 https://​academic.oup.com/​annonc/​article-​pdf/​26/​suppl_5/​v31/​6675007/​mdv199.pdf Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Girard N, Ruffini E, Marx A, Faivre-Finn C and Peters S, on behalf of the ESMO Guidelines Committee Ann Oncol 2015;26(suppl 5):v40-55 https://​academic.oup.com/​annonc/​article-pdf/​26/​suppl_5/​v40/​6675418/​mdv277.pdf ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) and consensus statements on the management of lung cancers (early-stage, locally advanced and metastatic non-small-cell lung cancer [NSCLC], and small-cell lung cancer [SCLC] and chest tumours (malignant pleural mesothelioma and thymic epithelial tumours). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-up. The ESMO CPGs and consensus statements on lung & chest tumours are intended to provide you with a set of recommendations for the best standards of care for lung & chest tumours, using evidence-based medicine. Implementation of ESMO CPGs and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-based management of lung & chest tumours. Please visit http://www.esmo.org or http://www.oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5281_2.1.0.0",
	"text":"2.0.0.0 Dx and personalised medicine 2.1.0.0 Overview Pathological diagnosis of all non-‍small-‍cell lung cancer (NSCLC) sample types should be made according to the 2015 World Health Organization (WHO) classification Specific tumour histological subtype should be given whenever possible and immunohistochemistry (IHC) is recommended to increase the specificity of diagnosis in the small sample setting and reduce the rate of NSCLC-‍NOS (not otherwise specified) to less than 10% of cases Adequate tissue material should be obtained for histological diagnosis and molecular testing Tumour rebiopsy at disease progression is recommended in sub-‍groups where it might guide subsequent treatment, such as the use of the third-‍generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) against T790M-‍mutated resistant tumours Two key driver-‍mutations – EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements, as shown in the table below – determine approved, selective pathway-‍directed systemic therapy EGFR mutation testing is recommended in all patients with advanced non-squamous cell carcinoma (NSCC), but not in patients with an unequivocal diagnosis of squamous cell carcinoma (SCC), except in never/‍former light smokers (<15 pack years) EGFR mutation testing should use validated methodology providing the test sensitivity required for the tumour content of the sample and an adequate coverage of mutations in exons 18–21 (at a minimum the most common activating mutations, exon 19 deletion and exon 21 L858R point mutation, including exon 20 T790M, associated with specific drug resistance) Routine testing for ALK rearrangements is recommended in NSCC and ALK and EGFR testing should be carried out simultaneously Break-‍apart fluorescence in situ hybridisation (FISH) is a key ALK test Multiplex systems are preferable, although multiplex polymerase chain reaction (PCR) or reverse transcription-polymerase chain reaction (RT-‍PCR) requires an adequate coverage of the many possible fusion genes and are limited by the availability of adequate quality nucleic acid and methodology validation IHC has a high positive and negative predictive value for ALK fusion and is used to screen patients for possible confirmatory ALK FISH testing It is being used widely in Europe as the primary test for prescribing ALK TKIs Similar approaches may be taken for ROS1 fusion gene testing in those centres with access to drugs active in this setting Next-‍generation sequencing (NGS) facilitates testing for multiple gene mutations and (less frequently) for ALK, RET and ROS1 gene fusions NGS testing panels will also provide data on HER2, BRAF and MET mutations FISH quantitative analysis might allow for the documentation of MET gene amplification There is an emerging use of IHC for the rapid screening of EGFR and BRAF mutations The use of programmed death ligand 1 (PD-L1) IHC has emerged as a requirement for selecting some patients for anti-‍programmed death 1 (PD1) or anti-‍PD-‍L1 immunotherapy"
},
{
	"page":"ENAS5281_2.2.0.0",
	"text":"2.2.0.0 A personalised medicine synopsis A PERSONALISED MEDICINE SYNOPSIS TABLE FOR METASTATIC NSCLC BIOMARKER METHOD USE LOE, GOR EGFR mutation Any appropriate validated method, subject to external quality assurance Used to select patients for EGFR TKI therapy, identifying those, with sensitising mutations, most likely to respond V, A ALK gene rearrangement Any appropriate validated method, subject to external quality assurance. Standard approach has been FISH, or less often, multiplex PCR or RT-‍PCR. Certain IHC approaches may be used as a substitute primary test. IHC may also be used to screen patients, positive cases confirmed by an orthogonal method (FISH, PCR) Used to select patients for ALK TKI therapy, identifying those, with a positive test, most likely to respond V, A ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridisation; GOR, grade of recommendation; LOE, level of evidence; NSCLC, non-small-cell lung cancer; PCR, polymerase chain reaction; RT-‍PCR, reverse transcription polymerase chain reaction; TKI, tyrosine kinase inhibitor"
},
{
	"page":"ENAS5281_3.1.0.0",
	"text":"3.0.0.0 STAGING AND RISK ASSESSMENT 3.1.0.0 Overview A complete medical history including smoking history and comorbidities, weight loss, performance status (PS) and physical examination is required Laboratory Standard tests, including routine haematology, renal and hepatic function and bone biochemistry tests, are required The routine use of serum markers, such as carcinoembryonic antigen (CEA), is not recommended Radiology A contrast-‍enhanced computed tomography (CT) scan of the chest and upper abdomen including complete assessment of liver, kidneys and adrenal glands is recommended Central nervous system (CNS) imaging with magnetic resonance imaging (MRI), preferably with gadolinium enhancement, or CT with iodine contrast should be carried out at diagnosis in patients with neurological symptoms or signs MRI is more sensitive than CT scan If metastatic disease has been determined by CT scan, other imaging is only necessary if it has an impact on treatment strategy Bone imaging is required if bone metastases are clinically suspected. Positron emission tomography (PET)-CT is the most sensitive modality in detecting bone metastasis MRI can be useful in documenting a localised bone metastasis Fluorodeoxyglucose (FDG)–PET-‍CT scan offers the highest sensitivity for mediastinal lymph nodes and distant metastasis assessment NSCLC is staged according to the American Joint Committee on Cancer (AJCC)/ Union for International Cancer Control (UICC) TNM (tumour-‍node-metastasis) system (7th edition) and is grouped into the stage categories shown in these tables The eighth edition of the TNM staging system has been officially accepted by the UICC and AJCC and globally implemented in 2017; of note, the AJCC has delayed its implementation of the eighth edition until 2018 Measurement of lesions should follow Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Where a solitary metastatic lesion is identified on imaging studies, including pleural and pericardial effusion, cytological or histological confirmation of stage IV disease is recommended"
},
{
	"page":"ENAS5281_3.2.0.0",
	"text":"3.2.0.0 TNM staging AJCC/UICC TNM STAGING SYSTEM, 7TH EDITION PRIMARY TUMOUR (T) TX Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualised by imaging or bronchoscopy T0 No evidence of primary tumour Tis Carcinoma in situ T1 Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)* T1a Tumour 2 cm or less in greatest dimension T1b Tumour more than 2 cm but 3 cm or less in greatest dimension T2 Tumour more than 3 cm but 7 cm or less or tumour with any of the following features (T2 tumours with these features are classified T2a if 5 cm or less); Involves main bronchus, 2 cm or more distal to the carina; Invades visceral pleura (PL1 or PL2); Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung T2a Tumour more than 3 cm but 5 cm or less in greatest dimension T2b Tumour more than 5 cm but 7 cm or less in greatest dimension T3 Tumour more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumour in the main bronchus (less than 2 cm distal to the carina* but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumour nodule(s) in the same lobe T4 Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina, separate tumour nodule(s) in a different ipsilateral lobe Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastases N1 Metastasis in ipsilateral peribronchial and/‍or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension N2 Metastasis in ipsilateral mediastinal and/‍or subcarinal lymph node(s) N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s) Distant Metastasis (M) M0 No distant metastasis M1 Distant metastasis M1a Separate tumour nodule(s) in a contralateral tumour with pleural nodules or malignant pleural (or pericardial) effusion† M1b Distant metastasis * The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1a †Most pleural (and pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple cytopathologic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is non-‍bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging element and the patient should be classified as M0 AJCC, American Joint Committee on Cancer; TNM, tumour node metastasis; UICC, Union for International Cancer Control Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook. 7th ed. New York, NY.: Springer, 2010) Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Handbook, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com."
},
{
	"page":"ENAS5281_3.3.0.0",
	"text":"3.3.0.0 Anatomic stage/‍ prognostic groups ANATOMIC STAGE/PROGNOSTIC GROUPS ACCORDING TO THE AJCC/UICC TNM STAGING SYSTEM, 7TH EDITION ANATOMIC STAGE/‍PROGNOSTIC GROUPS Occult carcinoma TX N0 M0 Stage 0 Tis N0 M0 Stage IA T1a,b N0 M0 Stage IB T2a N0 M0 Stage IIA T2b N0 M0   T1a,b N1 M0   T2a N1 M0 Stage IIB T2b N1 M0   T3 N0 M0 Stage IIIA T1a,b, T2a,b N2 M0   T3 N1, N2 M0   T4 N0, N1 M0 Stage IIIB T4 N2 M0   Any T N3 M0 Stage IV Any T Any N M1 AJCC, American Joint Committee on Cancer; Tis, carcinoma in situ; TNM, tumour node metastasis; UICC, Union for International Cancer Control Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook. 7th ed. New York, NY.: Springer, 2010) Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Handbook, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com."
},
{
	"page":"ENAS5281_4.1.0.0",
	"text":"MANAGEMENT OF ADVANCED/METASTATIC DISEASE 4.0.0.0 Mgmt. of advanced/ metastatic disease 4.1.0.0 Overview The treatment strategy should be discussed within a multidisciplinary tumour board and should take into account histology, molecular pathology, age, PS, comorbidities and the patient’s preferences Systemic therapy should be offered to all stage IV patients with PS 0–2 At all stages of NSCLC, smoking cessation improves outcome and should be greatly encouraged Management algorithms for stage IV SCC and NSCC are shown in the tool, stage IV SCC see here, stage IV NSCC see here"
},
{
	"page":"ENAS5281_4.3.1.0",
	"text":"4.3.0.0 First-‍line treatment 4.3.1.0 EGFR- and ALK-‍negative disease Chemotherapy with platinum-‍doublets should be considered in all stage IV NSCLC patients with EGFR- and ALK-‍negative disease, without major comorbidities and PS 0–2 Benefits of chemotherapy are observed irrespective of age, sex, histology and PS Platinum-‍based doublet therapy is the recommendation for patients with no contraindications to platinum compounds The recommendation is either 4 cycles of platinum-‍based doublets followed by less toxic maintenance monotherapy, or 4 up to a maximum of 6 cycles in patients not suitable for maintenance monotherapy Cisplatin-‍based combinations generally show higher efficacy than carboplatin-‍based combinations Cisplatin-‍based chemotherapy is associated with more gastrointestinal adverse events (AEs) and neurotoxicity and nephrotoxicity, while bone marrow toxicity is more common with carboplatin The albumin-‍bound paclitaxel (nab–paclitaxel)/carboplatin (nab-‍PC) combination has response rate (RR) benefits over solvent-‍based paclitaxel/carboplatin, with less neurotoxicity, particularly in SCC Based on the results of the frontline randomised Keynote 024 trial – assessing progression-free survival (PFS) under frontline pembrolizumab monotherapy as compared with platinum-based chemotherapy for metastatic NSCLC in adults whose tumours express PD-L1 with a ≥ 50% tumour proportion score and no EGFR or ALK mutations – pembrolizumab was approved in January 2017 by the European Medicines Agency (EMA)"
},
{
	"page":"ENAS5281_4.3.2.0",
	"text":"4.3.2.0 SCC Platinum-‍based doublets with the addition of a third-‍generation cytotoxic agent (gemcitabine, vinorelbine, taxanes), including the nab-‍PC regimen, are recommended in advanced SCC patients without major comorbidities and PS 0–2 Necitumumab, an immunoglobulin G1 (IgG1) monoclonal antibody against EGFR, added to cisplatin and gemcitabine improves survival over cisplatin/gemcitabine in IHC-‍identified EGFR expressing advanced SCC and the combination is recommended as a first-‍line treatment option in this setting. Necitumumab is administered up to 6 cycles of treatment followed by necitumumab as a single agent until disease progression or unacceptable toxicity In patients with tumours expressing PD-L1 in ≥ 50% of tumour cells, pembrolizumab is the frontline treatment of choice"
},
{
	"page":"ENAS5281_4.3.3.0",
	"text":"4.3.2.0 NSCC Platinum-‍based doublets with a third-‍generation agent, including gemcitabine, vinorelbine, taxanes or nab-‍PC, can be used in NSCC Pemetrexed-‍based combination chemotherapy shows survival benefits over gemcitabine-‍ or docetaxel-‍based combinations and is the preferred treatment option Pemetrexed use should be restricted to NSCC in any line of treatment The survival benefits of pemetrexed in combination with cisplatin compared with carboplatin have not been investigated in a randomised trial Adding bevacizumab to paclitaxel/carboplatin in patients with NSCC and PS 0–1 improves survival and bevacizumab plus platinum-‍based chemotherapy is an option for such patients in the absence of contraindications In patients with tumours expressing PD-L1 in ≥ 50% of tumour cells and with no EGFR or ALK mutations, pembrolizumab is the frontline treatment of choice"
},
{
	"page":"ENAS5281_4.4.0.0",
	"text":"4.4.0.0 PS 2 and beyond Chemotherapy prolongs survival and improves quality of life (QoL) compared with best supportive care (BSC) in NSCLC patients with PS 2 Platinum-‍based doublets have superior efficacy to monotherapy, despite an increase in toxicities (mainly haematological), and platinum (preferably carboplatin)-‍based doublets should be considered for eligible PS 2 patients Single-‍agent chemotherapy with gemcitabine, vinorelbine and docetaxel represents an alternative treatment option The relationship of PS to either tumour burden or comorbidities, and its corresponding likelihood of improving or deteriorating during treatment, should be considered and treatment risks and benefits discussed with patient There are no data to support the use of front-‍line cytotoxic treatment over BSC alone in PS > 2 patients and poor PS (3–4) patients should be offered BSC in the absence of documented activating (sensitising) EGFR mutations or ALK rearrangements"
},
{
	"page":"ENAS5281_4.5.0.0",
	"text":"4.5.0.0 Elderly patients Doublet therapy shows greater efficacy, but increased toxicity, compared with single-‍agent therapy Platinum-‍based chemotherapy is recommended for elderly patients (70–89 years) with PS 0–2 and adequate organ function The tolerability of nab-‍PC in patients aged ≥ 70 years is comparable to that in younger patients A single-‍agent approach (vinorelbine, gemcitabine, docetaxel) is recommended for unfit or co-‍morbid patients, who are more likely to develop a higher incidence of treatment-‍related AEs Comprehensive geriatric assessment (CGA) can predict morbidity and mortality in elderly patients with cancer and to adapt cancer management to each patient’s fitness or frailty, although this has not been related to survival benefits"
},
{
	"page":"ENAS5281_4.6.0.0",
	"text":"4.6.0.0 Maintenance Maintenance therapy should be offered only to patients with PS 0–1 after first-‍line chemotherapy and decisions must take into account histology, residual toxicity after first-‍line chemotherapy, response to platinum-‍doublet, PS and patient preference Pemetrexed switch maintenance (i.e. introduction after 4 cycles of platinum-‍ based chemotherapy) should be considered in NSCC patients with PS 0–1 Pemetrexed continuation maintenance (i.e. continuation following completion of 4 cycles of first-‍line cisplatin/pemetrexed chemotherapy) is recommended in NSCC, in the absence of progression after first-‍line chemotherapy and upon recovery from toxicities from the previous treatment Erlotinib switch maintenance is recommended only for NSCLC patients with locally advanced or metastatic NSCLC with EGFR-‍activating mutations The contribution of the maintenance phase of studies to the demonstrated survival benefit of bevacizumab, cetuximab or necitumumab, administered concomitantly to chemotherapy and further continued as monotherapy until disease progression, has not been established"
},
{
	"page":"ENAS5281_4.7.1.0",
	"text":"4.7.0.0 Second-‍line Tx 4.7.1.0 EGFR- and ALK-‍negative disease Second-‍line therapy should be offered to patients clinically or radiologically progressing after first-‍line chemotherapy, irrespective of administration of maintenance chemotherapy, and with PS 0–2 Options comprise pemetrexed (for NSCC only) or docetaxel, with combination chemotherapy regimens showing no additional benefit over single agents, which can improve symptoms and survival Erlotinib is a potential second-‍line option in pretreated patients not eligible for further chemotherapy, including patients with PS 3, and with unknown EGFR status or EGFR wild type (WT) Efficacy is limited compared with chemotherapy in EGFR WT disease Ramucirumab, a vascular endothelial growth factor receptor-‍2 (VEGFR2) inhibitor, combined with docetaxel is a treatment option in second-‍line treatment for advanced NSCLC with PS 0–1, as per trial inclusion criteria, and selected PS 2 patients, regardless of histology Second-‍line treatment duration should be individualised, and treatment may be prolonged if disease is controlled and toxicity acceptable Nivolumab, a fully IgG4 PD-1 immune checkpoint inhibitor, is an additional treatment options in second line NSCLC, as discussed in the following sections Pembrolizumab is another IgG4 anti-‍PD-‍1 monoclonal antibody that has received EMA approval for the treatment of any histological type of NSCLC after failure of first-‍line therapy in patients with tumours expressing PD-L1"
},
{
	"page":"ENAS5281_4.7.2.0",
	"text":"4.7.2.0 SCC Nivolumab improves survival, is better tolerated and may improve QoL compared with docetaxel in previously treated SCC. PD-L1 expression is neither prognostic nor predictive of clinical benefit Nivolumab at 3 mg/kg every 2 weeks is recommended in pretreated patients with platinum pretreated advanced SCC Pembrolizumab at 2 mg/kg every 3 weeks is recommended in pretreated patients with platinum-‍pretreated, advanced SCC expressing PD-L1 Afatinib improves survival compared with erlotinib in advanced SCC and is recommended as additional option for the treatment of Eastern Cooperative Oncology Group (ECOG) PS 0–2 patients with unknown EGFR status or EGFR WT disease Ramucirumab combined with docetaxel is a treatment option in second-‍line treatment for advanced SCC"
},
{
	"page":"ENAS5281_4.7.3.0",
	"text":"4.7.3.0 NSCC Pemetrexed Pemetrexed is as effective as docetaxel in NSCC and better tolerated, with lower rates of neutropaenia, alopecia and gastrointestinal AEs, and is a treatment option for those patients with NSCC not receiving it as first-‍line therapy Docetaxel and nintedanib The combination of docetaxel and the angiokinase inhibitor nintedanib prolongs survival in NSCC compared with docetaxel, particularly in patients with fast-progressing disease or refractory to first-‍line chemotherapy Nivolumab Nivolumab shows a survival benefit compared with docetaxel in PD-L1-‍positive pretreated NSCC and similar benefits to docetaxel in PD-L1-‍negative tumours but with a more favourable toxicity profile Nivolumab is associated with a lower frequency of serious adverse events (SAEs) and AEs leading to treatment discontinuation compared with docetaxel Nivolumab at 3 mg/kg every 2 weeks represents a treatment option in pretreated patients with advanced NSCC Pembrolizumab Pembrolizumab at 2 mg/kg every 3 weeks is recommended in pretreated patients with platinum-‍pretreated, advanced NSCC expressing PD-L1 Docetaxel and ramucirumab Ramucirumab combined with docetaxel is a treatment option in second-‍line treatment for advanced SCC"
},
{
	"page":"ENAS5281_4.8.1.0",
	"text":"4.8.0.0 EGFR-‍mutated NSCLC pts 4.8.1.0 Overview The treatment algorithm for EGFR-‍mutated NSCLC is shown in the figure here EGFR TKIs (gefitinib, erlotinib and afatinib) represent the standard-‍of-‍care for first-‍line treatment for advanced NSCLC with an activating (sensitising) EGFR mutation All patients with advanced NSCC, and patients with SCC who are never/‍former light smokers (< 15 pack years), undergo tumour EGFR mutational analysis at diagnosis and results should preferably be available before initiation of first-‍line treatment Patients with PS 3–4 may also be offered an EGFR TKI, as they are likely to receive a similar clinical benefit to patients with good PS Afatinib achieves higher RR and longer PFS than gefitinib as first-‍line treatment for patients with advanced NSCLC with common activating mutations (del19 or L858R) Afatinib improves survival compared with chemotherapy in patients with EGFR del-19 mutations but not EGFR L858R mutations Should the information on EGFR sensitising mutations become available during first-‍line platinum-‍based chemotherapy, the recommendation is to continue chemotherapy for up to 4 cycles and then to offer maintenance EGFR TKI in those patients achieving disease control, or as second-‍line treatment at the time of progression The addition of bevacizumab to erlotinib improves PFS, with an increase in the incidence of non-‍serious, reversible AEs, and represents a first-‍line treatment option for EGFR-‍mutated disease Most patients will progress after 9–12 months of EGFR TKI treatment and such patients should undergo a rebiopsy to identify the EGFR T790M mutation, the most common cause of acquired TKI resistance A validated alternative to tissue rebiopsy is liquid biopsy; if a T790M mutation is detected, treatment with third-‍generation EGFR TKIs is justified, but if the liquid biopsy is T790M negative, a tissue rebiopsy is recommended Osimertinib, an oral, selective, third-‍generation, irreversible EGFR TKI inhibitor with activity against T790M mutation, is recommended (80 mg/‍day orally) for patients with EGFR T790M mutation When rebiopsy is not feasible or when the EGFR T790M mutation is not documented, the standard of care is platinum-‍based chemotherapy alone, with no data to support concurrent continuation of EGFR TKI In patients with asymptomatic radiological progression at a single site, continuation of the first-‍line EGFR TKI with local treatment (radiotherapy or surgery) can be considered on an individualised basis"
},
{
	"page":"ENAS5281_4.9.1.0",
	"text":"4.9.0.0 ALK-‍rearranged NSCLC patients 4.9.1.0 Overview The treatment algorithm for ALK-‍mutated NSCLC is shown in the figure here First-‍line treatment with crizotinib, a dual ALK and MET TKI, has been shown to improve PFS compared with cisplatin plus pemetrexed and is the preferred treatment for patients with ALK-‍rearranged NSCLC In the randomised ALEX open-label phase III trial, randomising patients with previously untreated, advanced ALK-positive NSCLC, alectinib showed superior efficacy and lower toxicity than crizotinib in primary treatment of ALK-positive NSCLC Crizotinib also improves PFS compared with chemotherapy (pemetrexed or docetaxel) in patients with previously treated ALK-‍rearranged NSCLC and is recommended as second-‍line treatment in this setting, if not previously administered The combination of continuing the ALK TKI with local treatment (radiotherapy or surgery) may represent a reasonable option and can be considered on an individualised basis All patients will eventually progress on crizotinib and treatment with a second-‍generation ALK inhibitor, such as ceritinib or alectinib, is recommended in this setting, and for patients who are intolerant to crizotinib A number of additional ALK inhibitors, including alectinib and brigatinib, are in clinical development The new generation ALK inhibitors (ceritinib, alectinib, lorlatinib and brigatinib) are characterised by a higher CNS activity than crizotinib"
},
{
	"page":"ENAS5281_4.10.0.0",
	"text":"Role of radiotherapy in stage IV NSCLC 4.10.0.0 Role of RT in stage IV NSCLC Radiotherapy plays a major role in the symptom control of metastases, such as painful chest wall disease, superior vena cava syndrome, soft tissue or neural invasion, and can relieve neurological symptoms from spinal cord compression Radiotherapy is indicated in cases of haemoptysis, symptomatic airway obstruction and following surgery for CNS, and, sometimes, bone surgery"
},
{
	"page":"ENAS5281_4.11.0.0",
	"text":"Role of palliative surgery in stage IV NSCLC 4.11.0.0 Palliative surgery in stage IV NSCLC Recurrent pleural effusions can be managed by pleurodesis and the preferred sclerosing agent is talc, which is more effective than bleomycin or tetracycline Thoracoscopic insufflation with talc (poudrage) is more effective than talc slurry sclerosis If pleurodesis is not possible due to bronchial obstruction or trapped lung, or in the case of pleurodesis failure, recurrent pleural effusions may be managed by indwelling subcutaneous pleural catheters Surgery might be necessary in the case of significant local complications related to primary tumour or metastasis, like abscess, uncontrolled massive haemoptysis, spinal cord compression or pathological bone fracture"
},
{
	"page":"ENAS5281_4.12.0.0",
	"text":"Role of minimally-invasive procedures in stage IV NSCLC 4.12.0.0 Minim.-‍invasive proce. in IV NSCLC Endoscopic debulking by laser, cryotherapy or stent placement may be helpful for relief of symptomatic major airway obstruction or post-‍obstructive infection Endoscopy is useful in the diagnosis and treatment (endobronchial or by guiding endovascular embolisation) of haemoptysis Vascular stenting might be useful in NSCLC-‍related superior vena cava compression"
},
{
	"page":"ENAS5281_4.13.0.0",
	"text":"4.13.0.0 Role of palliative care in stage IV NSCLC Early palliative care intervention is recommended, in parallel with standard oncological care Palliative care may improve QoL, although the evidence remains scarce"
},
{
	"page":"ENAS5281_4.14.1.0",
	"text":"4.14.0.0 Focus on brain and bone metastases 4.14.1.0 Brain metastases The treatment of patients with brain metastases and no driver mutations is dependent on the prognosis, estimated by the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) RPA class III patients, who have a Karnofsky Performance Status (KPS) of < 70%, have a median survival of < 2 months and should not receive radiotherapy; BSC alone is recommended as management Stereotactic radiosurgery (SRS) or resection are recommended for single metastases For 2–3 metastases, SRS is recommended in patients with RPA class I–II There is no evidence to support the addition of whole brain radiotherapy (WBRT) to surgery or SRS For > 3 brain metastases, WBRT is recommended in patients with RPA class I–II, although its benefit compared with supportive care remains to be confirmed. However, SRS may also be a valid alternative to WBRT in fit patients with > 3 brain metastases WBRT schedules of 20 Gy in 5 fractions or 30 Gy in 10 fractions give similar results In patients with asymptomatic brain metastases who have not yet received prior systemic therapy (i.e. chemotherapy, TKIs), treatment with upfront systemic chemotherapy and deferred WBRT should be considered Dexamethasone (4 mg/‍day), or equivalent, is recommended for most patients with symptomatic brain metastases and/‍or significant oedema, with dose tapering and possible cessation following radiotherapy Corticosteroids are not recommended for asymptomatic brain metastases In patients with EGFR- or ALK-‍positive NSCLC with asymptomatic brain metastases, the use of next-‍generation TKIs is recommended, with the possibility of delaying cranial radiotherapy Treatment recommendations for symptomatic brain metastases are the same as for tumours without driver mutations In ALK-‍positive patients progressing on crizotinib, treatment with EMA approved ceritinib or alectinib shows activity against CNS disease"
},
{
	"page":"ENAS5281_4.14.2.0",
	"text":"4.14.2.0 Bone metastases 30%–40% of patients with NSCLC develop bone metastases and it may be reasonable to evaluate for bone disease upon disease diagnosis Zoledronic acid reduces skeletal-related events (SREs) (pathological fracture, radiation or surgery to bone, or spinal cord compression) and is recommended in stage IV bone metastatic disease Denosumab is not inferior to zoledronic acid, and shows a trend toward superiority, in terms of SRE prevention in advanced NSCLC and may improve QoL"
},
{
	"page":"ENAS5281_4.15.0.0",
	"text":"Treatment of oligometastatic NSCLC 4.15.0.0 Tx of oligometastatic NSCLC Stage IV patients with 1–3 synchronous metastases at diagnosis may experience long-‍term disease-‍free survival (DFS) following systemic therapy and radical local treatment (high-‍dose radiotherapy or surgery) based on retrospective data, although inclusion in clinical trials is preferred due to the limited evidence available. Multiple synchronous metastases should be treated within prospective clinical trials For solitary contralateral lung lesions, review by a multidisciplinary tumour board is recommended, followed by radical therapy, such as that for a synchronous secondary primary tumour, with both surgery and SRS resulting in long-‍term survival Based on analysis of the International Association for the Study of Lung Cancer (IASLC) in the 8th TNM classification, categories of M1b for a single metastatic lesion in a single distant organ and M1c for either multiple metastases to a single organ or for multiple lesions to multiple organs have been added to allow for evaluation of staging and outcomes data for these patient subgroups There is currently a lack of prospective data to favour specific treatment recommendations for M1a and M1b disease, notably regarding the use of local therapies, in that setting There is currently a lack of prospective data to support the use of ablative techniques, such as stereotactic ablative radiotherapy (SABR) or surgery, for oligoprogression (clonal progression of a limited number of metastatic lesions) in patients with driver mutations"
},
{
	"page":"ENAS5281_5.0.0.0",
	"text":"5.0.0.0 RESPONSE EVALUATION Response evaluation is recommended after 2–3 cycles of chemotherapy, using the same initial radiographic investigation that demonstrated tumour lesions The same procedure and timing (every 6–9 weeks) should be applied for the response evaluation in patients treated with targeted therapies and/‍or immunotherapy Follow-‍up with PET is not routinely recommended, due to its high sensitivity and relatively low specificity Measurements and response reporting should follow RECIST v1.1, although its adequacy in evaluating response to EGFR or ALK TKI remains debatable Immune-related response criteria (irRC) have been proposed and validated in malignant melanoma to better assess the variety of possible responses generated. In NSCLC, in the case of immune checkpoint inhibitor therapy, RECIST criteria should be used, although irRC may have a role in the overall assessment of therapy"
},
{
	"page":"ENAS5281_6.0.0.0",
	"text":"6.0.0.0 FOLLOW-‍UP The optimal approach to post-‍treatment management of patients with NSCLC, including the role of radiological evaluation, is controversial, with very limited literature available Close follow-‍up, at least every 6–12 weeks after first-‍line therapy, is advised, but should also depend on individual re-‍treatment options"
},
{
	"page":"ENAS5281_7.1.0.0",
	"text":"DIAGNOSIS AND PERSONALISED MEDICINE 7.0.0.0 Summary of recommendations 7.1.0.0 Dx and personalised medicine Pathological diagnosis of all NSCLC sample types should be made according to the 2015 WHO classification Specific tumour histological subtype should be given whenever possible and IHC is recommended to increase the specificity of diagnosis in the small sample setting and reduce the rate of NSCLC-‍NOS to <10% of cases [IV, A] Tumour rebiopsy at disease progression is recommended in sub-‍groups where it might guide subsequent treatment [IV, A] EGFR mutation testing is recommended in all patients with advanced NSCC [I, A], but not in patients with an unequivocal diagnosis of SCC, except in never/‍former light smokers (<15 pack years) [IV, A] EGFR mutation testing should use validated methodology providing the test sensitivity required for the tumour content of the sample and an adequate coverage of mutations in exons 18–21 (at a minimum the most common activating mutations, exon 19 deletion and exon 21 L858R point mutation including exon 20 T790M) [I, A] Routine testing for ALK rearrangements is recommended in NSCC [II, A] and ALK and EGFR testing should be carried out simultaneously Multiplex systems are preferable [III, A] IHC is widely used to screen patients for possible confirmatory ALK FISH testing NGS facilitates testing for multiple gene mutations and (less frequently) for ALK , RET and ROS1 gene fusions [III, A] NGS testing panels will also provide data on HER2, BRAF and MET mutations FISH quantitative analysis might allow for the documentation of MET gene amplification"
},
{
	"page":"ENAS5281_7.2.0.0",
	"text":"7.2.0.0 Staging and risk assessment A complete medical history including smoking history and comorbidities, weight loss, PS and physical examination is required Laboratory Standard tests, including routine haematology, renal and hepatic function and bone biochemistry tests, are required, but routine use of serum markers is not recommended Radiology A contrast-‍enhanced CT scan of the chest and upper abdomen including complete assessment of liver, kidneys and adrenal glands is recommended CNS imaging with MRI or CT with iodine contrast should be carried out at diagnosis in patients with neurological symptoms or signs Bone imaging is required if bone metastases are clinically suspected, preferably with PET-‍CT, and MRI can be useful in documenting a localised bone metastasis FDG–PET-‍CT scan offers the highest sensitivity for mediastinal lymph nodes and distant metastasis assessment NSCLC is staged according to the AJCC/‍UICC TNM system (7th edition) The eighth edition of the TNM staging system has been officially accepted by the UICC and AJCC and globally implemented in 2017; of note, the AJCC has delayed its implementation of the eighth edition until 2018 Measurement of lesions should follow RECIST v1.1 Where a solitary metastatic lesion is identified on imaging studies, cytological or histological confirmation of stage IV disease is recommended"
},
{
	"page":"ENAS5281_7.3.1.0",
	"text":"7.3.0.0 Mgmt. of advanced/ metastatic disease 7.3.1.0 Overview The treatment strategy should be discussed within a multidisciplinary tumour board and should take into account histology, molecular pathology, age, PS, comorbidities and the patient’s preferences Systemic therapy should be offered to all stage IV patients with PS 0–2 [I, A] At all stages of NSCLC, smoking cessation improves outcome and should be greatly encouraged [II, A]"
},
{
	"page":"ENAS5281_7.3.2.1",
	"text":"7.3.2.0 First-‍line treatment 7.3.2.1 EGFR- and ALK-‍negative disease Chemotherapy with platinum-‍doublets should be considered in all stage IV NSCLC patients with EGFR- and ALK-‍negative disease, without major comorbidities and PS 0–2 [I, A] Platinum-‍based doublets are recommended for patients with no contraindications to platinum compounds [I, A] The recommendation is either 4 cycles of platinum-‍based doublets followed by less toxic maintenance monotherapy, or 4 up to a maximum of 6 cycles in patients not suitable for maintenance monotherapy [I, A] Cisplatin-‍based combinations generally show higher efficacy than carboplatin-‍based combinations [I, B] nab-‍PC has RR benefits over solvent-‍based paclitaxel/carboplatin, with less neurotoxicity, particularly in SCC [I, B]"
},
{
	"page":"ENAS5281_7.3.2.2",
	"text":"7.3.2.2 SCC Platinum-‍based doublets with the addition of a third-‍generation cytotoxic agent (gemcitabine, vinorelbine, taxanes) [I, A], including the nab-‍PC regimen [I, B], are recommended in advanced SCC patients without major comorbidities and PS 0–2 Necitumumab plus cisplatin and gemcitabine is recommended as a first-‍line treatment option in IHC-‍identified EGFR-‍expressing advanced SCC [I, B; ESMO-Magnitude of Clinical Benefit Scale (MCBS) v1.0 score: 1] In patients with tumours expressing PD-L1 in ≥ 50% of tumour cells, pembrolizumab is the frontline treatment of choice [I, A]"
},
{
	"page":"ENAS5281_7.3.2.3",
	"text":"7.3.2.3 NSCC Platinum-‍based doublets with a third generation agent, including gemcitabine, vinorelbine or taxanes, can be used in NSCC Pemetrexed-‍based combination chemotherapy is the preferred treatment option [II, A] Pemetrexed use should be restricted to NSCC in any line of treatment [I, A] Bevacizumab plus platinum-‍based chemotherapy is an option for patients with NSCC and PS 0–1 in the absence of contraindications [I, A] Based on the results of the frontline randomised Keynote 024 trial – assessing PFS under pembrolizumab monotherapy for the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 with a ≥ 50% tumour proportion score with no EGFR or ALK positive tumour mutations as compared with platinum-based chemotherapy – pembrolizumab was approved in January 2017by the EMA In patients with tumours expressing PD-L1 in ≥ 50% of tumour cells and with no EGFR or ALK mutations, pembrolizumab is the frontline treatment of choice [I, A]"
},
{
	"page":"ENAS5281_7.3.3.0",
	"text":"7.3.3.0 PS 2 and beyond Chemotherapy prolongs survival and improves QoL compared with BSC in NSCLC patients with PS 2 [I, B] Platinum (preferably carboplatin)-‍based doublets should be considered for eligible PS 2 patients [II, A] Single-‍agent chemotherapy with gemcitabine, vinorelbine and docetaxel represents an alternative treatment option [I, B] Poor PS (3–4) patients should be offered BSC in the absence of documented activating (sensitising) EGFR mutations or ALK rearrangements [II, B]"
},
{
	"page":"ENAS5281_7.3.4.0",
	"text":"7.3.4.0 Elderly patients Platinum-‍based chemotherapy is recommended for elderly patients (70–89 years) with PS 0–2 and adequate organ function [I, B] The tolerability of nab-‍PC is comparable to that in younger patients A single-‍agent approach (vinorelbine, gemcitabine, docetaxel) is recommended for unfit or co-‍morbid patients [I, B], who are more likely to develop a higher incidence of treatment-‍related AEs CGA can predict morbidity and mortality in elderly patients with cancer and to adapt cancer management to each patient’s fitness or frailty [III, C]"
},
{
	"page":"ENAS5281_7.3.5.0",
	"text":"7.3.5.0 Maintenance Maintenance therapy should be offered only to patients with PS 0–1 after first-‍line chemotherapy and decisions must take into account histology, residual toxicity after first-‍line chemotherapy, response to platinum-‍doublet, PS and patient preference Pemetrexed switch maintenance (i.e. introduction after 4 cycles of platinum-‍based chemotherapy) should be considered in NSCC patients with PS 0–1 [I, B] Pemetrexed continuation maintenance (i.e. continuation following completion of 4 cycles of first-‍line cisplatin/pemetrexed chemotherapy) is recommended in NSCC, in the absence of progression after first-‍line chemotherapy and upon recovery from toxicities from the previous treatment [I, A] Erlotinib switch maintenance is recommended only for NSCLC patients with locally advanced or metastatic NSCLC with EGFR activating mutations [I, B]"
},
{
	"page":"ENAS5281_7.3.6.1",
	"text":"7.3.6.0 Second-‍line treatment 7.3.6.1 EGFR- and ALK-‍negative disease Second-‍line therapy should be offered to patients clinically or radiologically progressing after first-‍line chemotherapy, irrespective of administration of maintenance chemotherapy, and with PS 0–2 [I, A] Options comprise pemetrexed (for NSCC only) or docetaxel [I, B], with combination chemotherapy regimens showing no additional benefit over single agents Erlotinib is a potential second-‍line option in pretreated patients not eligible for further chemotherapy, including patients with PS 3, and with unknown EGFR status or EGFR WT [II, C] Ramucirumab combined with docetaxel is a treatment option in second-‍line treatment for advanced NSCLC with PS 0–1 and selected PS 2 patients, regardless of histology [I, B; ESMO-‍MCBS v1.0 score: 2] Second-‍line treatment duration should be individualised, and treatment may be prolonged if disease is controlled and toxicity acceptable [II, B] Nivolumab and pembrolizumab (in PD-L1-‍positive NSCLC patients only) are additional treatment options"
},
{
	"page":"ENAS5281_7.3.6.2",
	"text":"7.3.6.2 SCC Nivolumab at 3 mg/kg every 2 weeks is recommended in pretreated patients with platinum pretreated advanced SCC [I, A; ESMO-‍MCBS v1.0 score: 5] Pembrolizumab at 2 mg/kg every 3 weeks is recommended in pretreated patients with platinum-‍pretreated, advanced SCC expressing PD-L1 [I, A; ESMO-‍MCBS v1.0 score: 3 if PD-L1 > 1%; 5 if PD-L1 > 50%] Afatinib improves survival compared with erlotinib in advanced SCC and is recommended as additional option for the treatment of ECOG PS 0–2 patients with unknown EGFR status or EGFR WT disease [I, C; ESMO-‍MCBS v1.0 score: 1] Ramucirumab combined with docetaxel is a treatment option in second-‍line treatment for advanced SCC"
},
{
	"page":"ENAS5281_7.3.6.3",
	"text":"7.3.6.3 NSCC Pemetrexed Pemetrexed is as effective as docetaxel in NSCC and better tolerated and is a treatment option for those patients with NSCC not receiving it as first-‍line therapy [I, B] Docetaxel and nintedanib The combination of docetaxel and nintedanib should be considered as a second-‍line option in patients with AC, especially in those progressing within 9 months from the start of first-‍line chemotherapy [II, B] Nivolumab Nivolumab shows a survival benefit compared with docetaxel in PD-L1-‍positive pretreated NSCC [I, B] and similar benefits to docetaxel in PD-L1-‍negative tumours but with a more favourable toxicity profile [II, A] Nivolumab at 3 mg/kg every 2 weeks represents a treatment option in pretreated patients with advanced NSCC [I, B; ESMO-‍MCBS v1.0 score: 5] Pembrolizumab Pembrolizumab at 2 mg/kg every 3 weeks is recommended in pretreated patients with platinum-‍pretreated, advanced NSCC expressing PD-L1 [I, A; ESMO-‍MCBS v1.0 score: 3 if PD-L1 > 1%; 5 if PD-L1 > 50%] Docetaxel and ramucirumab Ramucirumab combined with docetaxel is a treatment option in second-‍line treatment for advanced SCC"
},
{
	"page":"ENAS5281_7.3.7.0",
	"text":"7.3.7.0 EGFR-‍mutated NSCLC patients EGFR TKIs (gefitinib, erlotinib and afatinib) represent the standard-‍of-‍care for first-‍line treatment for advanced NSCLC with an activating (sensitising) EGFR mutation [I, A] All patients with advanced NSCC, and patients with SCC who are never/‍former light smokers (<15 pack years), undergo tumour EGFR mutational analysis at diagnosis and results should preferably be available before initiation of first-‍line treatment [I, B] Patients with PS 3–4 may also be offered an EGFR TKI, as they are likely to receive a similar clinical benefit to patients with good PS [II, A] Afatinib achieves higher RR and longer PFS than gefitinib as first-‍line treatment for patients with advanced NSCLC with common activating mutations (del19 or L858R) [II, B] Afatinib improves survival compared with chemotherapy in patients with EGFR del19 mutations but not EGFR L858R mutations [II, A] Should the information on EGFR-‍sensitising mutations become available during first-‍line platinum-‍based chemotherapy, the recommendation is to continue chemotherapy for up to 4 cycles and then to offer maintenance EGFR TKI in those patients achieving disease control, or as second-‍line treatment at the time of progression [I, A] The addition of bevacizumab to erlotinib represents a first-‍line treatment option for EGFR-‍mutated disease [I, A; ESMO-‍MCBS v1.0 score: 2] Most patients will progress after 9–12 months of EGFR TKI treatment and such patients should undergo a rebiopsy to identify the EGFR T790M mutation A validated alternative to tissue rebiopsy is liquid biopsy [III, A]; if a T790M mutation is detected, treatment with third-‍generation EGFR TKIs is justified, but if the liquid biopsy is T790M negative, a tissue rebiopsy is recommended Osimertinib is recommended (80 mg/‍day orally) for patients with EGFR T790M mutation [III, A] When rebiopsy is not feasible or when the EGFR T790M mutation is not documented, the standard of care is platinum-‍based chemotherapy alone, with no data to support concurrent continuation of EGFR TKI [I, A] In patients with asymptomatic radiological progression at a single site, continuation of first-‍line EGFR TKI with local treatment (radiotherapy or surgery) can be considered on an individualised basis [III, B]"
},
{
	"page":"ENAS5281_7.3.8.0",
	"text":"7.3.8.0 ALK-‍rearranged NSCLC patients First-‍line treatment with crizotinib is the preferred treatment for patients with ALK-‍rearranged NSCLC [I, A] In the randomised ALEX open-label phase III trial, randomising patients with previously untreated, advanced ALK-positive NSCLC, alectinib showed superior efficacy and lower toxicity than crizotinib in primary treatment of ALK-positive NSCLC [I, A] Crizotinib is also recommended second-‍line in previously treated patients with ALK-‍rearranged NSCLC, if not previously administered [I, A] The combination of continuing the ALK TKI with local treatment (radiotherapy or surgery) may represent a reasonable option and can be considered on an individualised basis [III, B] Treatment with a second-‍generation ALK inhibitor, such as ceritinib or alectinib, is recommended for patients progressing on crizotinib or intolerant to crizotinib [III, A]"
},
{
	"page":"ENAS5281_7.3.9.0",
	"text":"7.3.9.0 Role of RT in stage IV NSCLC Role of radiotherapy in stage IV NSCLC Radiotherapy plays a major role in the symptom control of metastases Radiotherapy is indicated in cases of haemoptysis, symptomatic airway obstruction and following surgery for CNS, and, sometimes, bone surgery [II, B]"
},
{
	"page":"ENAS5281_7.3.10.0",
	"text":"7.3.10.0 Palliative surgery in stage IV NSCLC Recurrent pleural effusions can be managed by pleurodesis and the preferred sclerosing agent is talc, which is more effective than bleomycin or tetracycline [II, B] Thoracoscopic insufflation with talc (poudrage) is more effective than talc slurry sclerosis [II, B] If pleurodesis is not possible or fails, recurrent pleural effusions may be managed by indwelling subcutaneous pleural catheters Surgery might be necessary for significant tumour-‍ or metastasis-‍related local complications"
},
{
	"page":"ENAS5281_7.3.11.0",
	"text":"7.3.11.0 Minim.-‍invasive proce. in IV NSCLC Endoscopic debulking by laser, cryotherapy or stent placement may be helpful for relief of symptomatic major airway obstruction or post-‍obstructive infection [III, C] Endoscopy is useful in the diagnosis and treatment (endobronchial or by guiding endovascular embolisation) of haemoptysis [III, C] Vascular stenting might be useful in NSCLC-‍related superior vena cava compression [II, B]"
},
{
	"page":"ENAS5281_7.3.12.0",
	"text":"7.3.12.0 Role of palliative care in stage IV NSCLC Early palliative care intervention is recommended, in parallel with standard oncological care [II, A] and may improve QoL, although the evidence remains scarce"
},
{
	"page":"ENAS5281_7.3.13.1",
	"text":"7.3.13.0 Focus on brain and bone metastases 7.3.13.1 Brain metastases RPA class III patients, who have a KPS of < 70%, have a median survival of < 2 months and should not receive radiotherapy [I, B]; BSC alone is recommended as management SRS or resection are recommended for single metastases [II, B] For 2–3 metastases, SRS is recommended in patients with RPA class I–II [II, B] There is no evidence to support the addition of WBRT to surgery or SRS [I, A] For > 3 brain metastases, WBRT is recommended in patients with RPA class I–II [II, B], although its benefit compared with BSC is unconfirmed. SRS may be a valid alternative to WBRT in fit patients [IV, C] WBRT schedules of 20 Gy in 5 fractions or 30 Gy in 10 fractions give similar results [I, A] In patients with asymptomatic brain metastases who have not yet received prior systemic therapy, treatment with upfront systemic chemotherapy and deferred WBRT should be considered [II, B] Dexamethasone (4 mg/‍day), or equivalent, is recommended for most patients with symptomatic brain metastases and/‍or significant oedema [II, A], with dose tapering and possible cessation following radiotherapy Corticosteroids are not recommended for asymptomatic brain metastases In patients with EGFR- or ALK-‍positive NSCLC with asymptomatic brain metastases, the use of next-‍generation TKIs is recommended, with the possibility of delaying cranial radiotherapy [III, B] In ALK-‍positive patients progressing on crizotinib, treatment with EMA approved ceritinib or alectinib shows activity against CNS disease"
},
{
	"page":"ENAS5281_7.3.13.2",
	"text":"7.3.13.2 Bone metastases Evaluation of bone disease upon disease diagnosis is reasonable Zoledronic acid reduces SREs and is recommended in stage IV bone metastatic disease [II, B] Denosumab is not inferior to zoledronic acid [I, B], and shows a trend toward superiority, in terms of SRE prevention [II, B] in advanced NSCLC and may improve QoL"
},
{
	"page":"ENAS5281_7.3.14.0",
	"text":"7.3.14.0 Treatment of oligometastatic NSCLC Stage IV patients with 1–3 synchronous metastases at diagnosis may experience long-‍term DFS following systemic therapy and radical local treatment (high-‍dose radiotherapy or surgery) [III, B], although inclusion in clinical trials is preferred due to the limited evidence available. Multiple synchronous metastases should be treated within prospective clinical trials Stage IV patients with limited metachronous metastases may be treated with a radical local treatment as some may experience long-‍term DFS [III, B] For solitary contralateral lung lesions, review by a multidisciplinary tumour board is recommended, followed by radical therapy, such as that for a synchronous secondary primary tumour, with both surgery and SRS resulting in long-‍term survival [IV, B] There is currently a lack of prospective data to support the use of ablative techniques, such as SABR or surgery, for oligoprogression in patients with driver mutations [IV, C]"
},
{
	"page":"ENAS5281_7.4.0.0",
	"text":"7.4.0.0 RESPONSE EVALUATION Response evaluation is recommended after 2–3 cycles of chemotherapy, using the same initial radiographic investigation that demonstrated tumour lesions The same procedure and timing (every 6–9 weeks) should be applied for the response evaluation in patients treated with targeted therapies and/‍or immunotherapy Follow-‍up with PET is not routinely recommended Measurements and response reporting should follow RECIST v1.1"
},
{
	"page":"ENAS5281_7.5.0.0",
	"text":"7.5.0.0 FOLLOW-‍UP The optimal approach to post-‍treatment management of patients with NSCLC is controversial Close follow-‍up, at least every 6–12 weeks after first-‍line therapy, is advised, but should also depend on individual re-‍treatment options [III, B]"
},
{
	"page":"ENAS5281_8.0.0.0",
	"text":"8.0.0.0 Glossary ACCP American College of Chest Physicians ADOC doxorubicin/​‍cisplatin/​‍‍vincristine/​‍‍cyclophosphamide AE adverse event AHA/​ACC American Heart Association/​​American College of Cardiology AJCC American Joint Committee on Cancer ALK anaplastic lymphoma kinase AUC area under the curve BSC best supportive care CABG coronary artery bypass grafting CAG coronary angiography CAP cisplatin/​‍doxorubicin/​‍cyclophosphamide Cap-‍GEM capecitabine/​‍‍gemcitabine Carbo-‍Px carboplatin/​‍paclitaxel CAV cyclophosphamide/​‍‍doxorubicin/​‍‍vincristine CEA carcinoembryonic antigen CGA comprehensive geriatric assessment ChT chemotherapy CNS central nervous system CODE cisplatin/​‍‍vincristine/​‍‍doxorubicin/​‍etoposide COPD chronic obstructive pulmonary disease CPET cardiopulmonary exercise testing CPGs Clinical Practice Guidelines CRT chemoradiotherapy CT computed tomography DFS disease-‍free survival DLCO diffusing capacity for carbon monoxide EBUS endobronchial ultrasound ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EMA European Medicines Agency EPP extrapleural pneumonectomy ESMO European Society for Medical Oncology EUS oesophageal ultrasound FDG fluorodeoxyglucose FDG-‍PET 2-‍Fluoro-‍2-‍deoxy-‍D-‍glucose positron emission tomography FEV1 forced expiratory volume in 1 second FISH fluorescence in situ hybridisation FVC forced vital capacity GGO ground glass opacity GOR grade of recommendation IASLC International Association for the Study of Lung Cancer IgG1 immunoglobulin G1 IHC immunohistochemistry ILD interstitial lung disease IMIG International Mesothelioma Interest Group IMRT intensity-‍modulated radiotherapy IPF idiopathic pulmonary fibrosis irRC immune-‍related response criteria ITMIG International Thymic Malignancy Interest Group IV intravenous KPS Karnofsky Performance Status LDCT low-dose computed tomography LDH lactate dehydrogenase LN lymph node LOE level of evidence LVRS lung volume reduction surgery MCBS Magnitude of Clinical Benefit Scale MDT multidisciplinary team MEN1 multiple endocrine neoplasia 1 gene MPM malignant pleural mesothelioma MRI magnetic resonance imaging mTOR mammalian target of rapamycin nab-‍PC albumin-‍bound paclitaxel/​‍carboplatin NGS next-‍generation sequencing NOS not otherwise specified NPV negative predictive value NSCC non-‍squamous cell carcinoma NSCLC non-‍small-‍cell lung cancer P/D pleurectomy/​‍decortication PCI prophylactic cranial irradiation PCR polymerase chain reaction PD-1 programmed death 1 PD-L1 programmed death ligand 1 PE cisplatin and etoposide PET positron emission tomography PET-CT positron emission tomography-computed tomography PFS progression-‍free survival PORT postoperative radiotherapy ppo predictive postoperative PS performance status QoL quality of life R0 resection with negative margins R1 resection with microscopic residual disease R2 resection with macroscopic residual disease RCRI revised cardiac risk index RECIST Response Evaluation Criteria In Solid Tumours RFA radiofrequency ablation RPA recursive partioning analysis RR response rate RT radiotherapy RT-‍PCR reverse transcription polymerase chain reaction RTOG Radiation Therapy Oncology Group RV reserve volume SABR stereotactic ablative radiotherapy SAE serious adverse event SBRT stereotactic body radiotherapy SCC squamous cell carcinoma SCLC small-‍cell lung cancer SRE skeletal-‍related events SRS stereotactic radiosurgery SUVmax maximum standardised uptake values TIA transient ischaemic attack Tis carcinoma in situ TKI tyrosine kinase inhibitor TLC total lung capacity TNM tumour-‍node-‍metastasis TPS tumour proportion score UICC Union for International Cancer Control VAM video-assisted mediastinoscopy VATS video-‍assisted thoracoscopy VEGFR2 vascular endothelial growth factor receptor-2 VIP etoposide/​ifosfamide/​cisplatin VO2 oxygen consumption VO2 max maximal oxygen consumption WBRT whole brain radiotherapy WHO World Health Organization WT wild type"
}
]